416 results about "Hypersensitive response" patented technology

Transgenic mice which constitutively express an antibody-type molecule encoded by the transgene and which has an IgE heavy chain constant region and is specific for a pre-defined antigen, provide an allergic reaction to that antigen without prior sensitization and are useful as allergy models.

The present invention generally concerns an epinephrine formulation that has enhanced stability. In particular embodiments, the formulation is an injectable formulation. In specific aspects, the formulation comprises epinephrine, EDTA, and one or more of an antioxidant such as cysteine, citric acid, acetylcysteine, or thioglycerol. The formulations are suitable for any medical condition that is in need of epinephrine, although in specific embodiments the medical condition is anaphylaxis, asthma, or cardiac arrest.

The invention describes a method of producing extracts from the seeds of meadowfoam, brassicas and crambe plants. A number of subsidiary processes and steps are shown in order to extract differing fractions of oil. Products produced from the above method are also described including uses and methods of these products which include a variety of skin conditions including eczema, facial eczema, dermatitis, external ulcers, welts, rashes, insect bites, allergic reactions and other irritations, burns, wounds, psoriasis, acneiform eruptions, dryness, dry skin, irritation, skin atrophy, secondary infections and the like. The extracts are also described as being a useful compound for treatment of the symptoms of such skin conditions as described above. In particular the use and extraction of glucosinolate (GSL), thiocyanates (TCL) and isothiocyanates (ITCL) is described.

Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

Compositions and methods of using the compositions for wound healing are provided. The compositions include one or more digestive enzymes, for example, one or more protease, lipases, and amylases. The compositions can be formulated as topical pharmaceutical compositions and can be used for faster healing through stimulation of epidermal cells in the absence of scarring. The compositions may deposit a short term fibrosis and help prevent re-opening of wounds. The compositions may improve recruitment of white blood cells, thereby inducing or enhancing growth factor and immune system activation via an enzyme antibiotic effect. The compositions may enhance the epidermal integrity beyond that of the normal physiological restorative process. Application of the compositions may result in greater re-growth of hair on regions of wounds healed with enzyme and reduced alopecia. The compositions may be administered without causing allergic reactions and without causing biological damage or burns.

The invention discloses a moisturizing cosmetic and a preparation method thereof. The moisturizing cosmetic is prepared from the components of rosa damascena extract, rosa canina fruit oil, undaria pinnatifida extract and the like. By adopting the unique prescription, the cosmetic can form a protective barrier on the surface layer of the skin of a user, ensures high skin absorption rate and good moisturizing effect, can effectively prevent the skin from being dry, and has the advantages of no skin stimulus or allergy to the skin, security and effectiveness.

The present invention provides compositions and methods of inhibiting or inducing activation of T cells in a patient. The methods comprise administering a therapeutically effective dose of pharmaceutical compositions comprising a pharmaceutically acceptable carrier and peptides of between about 4 and about 20 residues, that bind antigen binding sites on MHC molecules encoded by substantially all alleles of a DR locus. These peptides are referred to as pan DR binding peptides. The pan DR binding peptides can be used to inhibit immune responses associated with immunopathologies, such as autoimmunity, allograft rejection and allergic responses. The peptides can also be used in combination with CTL peptides to enhance a CTL response.

The present invention pertains to the use of probiotics for the preparation of a carrier for balancing the skin's immune function. In particular, the present invention pertains to the use of probiotic micro-organisms for balancing the skin's immune function under stress conditions, such as a exposure to ultraviolet radiation, specifically for enhancing the skin's immune activity and reducing the tendency to develop allergic reactions under such conditions.

A Chinese medicine for treating hypertension, hyperlipemia and hyperglycemia is prepared from 22 Chinese-medicinal materials including chrysanthemum flower, astragalus root, red sage root, haw, etc.

Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL / sec to less than 1 mL / min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.

A medicinal preparation is desired which has no harmful side effects such as hypersensitive reaction, heightens the water solubility of a sparingly water-soluble anticancer agent, maintains a high drug concentration in the blood, accumulates a drug in a tumor tissue at a high concentration, heightens the pharmacological effect of the sparingly water-soluble anticancer agent, and diminishes the side effects of the anticancer agent. Provided are: a novel block copolymer which can be a drug carrier having no harmful side effects such as hypersensitive reaction; a micelle preparation in which micelles are formed and which contains a sparingly water-soluble anticancer agent, especially paclitaxel, incorporated in the micelles in an amount necessary for a disease treatment without bonding it to the block copolymer and which can heighten the solubility of the drug in water; and an anticancer agent which comprises the micelle preparation as a medical ingredient, maintains a high concentration in the blood, has more potent drug activity, and is reduced in toxicity.

The present invention is related generally to a method for screening subjects to determine those subjects more likely to exhibit a hypersensitivity to allergen in the presence of airborne pollutants, such subject having a GSTM1 null genotype and / or a GSTP1 Ile / Ile genotype. This invention also provides novel or improved pharmaceutical compositions and therapeutic strategies for the treatment of immune diseases resulting from inappropriate or unwanted immune response such as allergic reactions.

Methods for detecting nonactivated basophils in a whole blood sample obtained from a normal healthy subject, methods for determining a subject's susceptibility to an allergic reaction to an allergen, where the subject has no known allergy to the allergen, methods for measuring a response to challenge with a potential allergen in a whole blood sample obtained from a subject with known allergic reactivity to allergens other than the potential allergen; and an in vitro system for reliable detection or quantification of a specific white blood cell population in a whole blood sample are described.

The present invention pertains to novel strains of lactic acid bacteria capable of reducing an individual's tendency to react allergic against a variety of different allergens. In particular, the present invention relates to recombinant strains of lactic acid bacteria that express surface polypeptides which include peptides or antibody fragments acting as mimic for at least a part of the Fc region of IgE-molecules. The invention also pertains to food or pharmaceutical compositions containing said micro-organisms or active fractions thereof.

The invention relates to a fragrant microcapsule type finishing agent which comprises the following constituents by mass percentage: 35-45 percent of fragrant nano microcapsule, 35-45 percent of thickening agent, 15-25 percent of adhesive and 1-5 percent of color paste, wherein the sum of the percentages of all the constituents is 100 percent. The invention also discloses a nano microcapsule type dry garment piece which has lasting fragrance more than 1 year, is sterile, has high safety, has no stimulation to the skin and no allergic response, and is suitable for fragrance finishing and storing of fabrics and ready-to-wear clothing made of cotton, wool, silk, linen and chemical fiber; and the fragrant nano microcapsule has good particle dispersivity on base cloth and is extremely easy to embed into the base cloth tissue structure.

A modified serum albumin is provided which has been modified at position cysteine 34 of human serum albumin, or at equivalent locations in other mammalian serum albumins, with an amino acid which lacks a sulphydryl group and will thus be less reactive with biological or chemical molecules such as trace metals at this site. Particularly suitable amino acids to substitute for cysteine at position 34 include methionine and other amino acids which are less reactive than cysteine and which maintain the same folding and antigenicity of the native serum albumin. The modified albumin of the present invention is advantageous in that it is binding to trace metals and other contaminants is reduced or eliminated, and it can thus be used more safely and effectively than unmodified albumin with a reduced or eliminated likelihood of causing an allergic reaction in the human being treated with the albumin composition.

The invention relates to a reconstructed ovum of an albinism model pig and a construction method thereof, and a construction method of the model pig. According to the construction method of the reconstructed ovum, tyrosinase is knocked out to obtain the reconstructed ovum of the albinism model pig. The combination of a CRISPP / Cas9 gene knock-out technique and a somatic nucleus transplantation technique proves that the method for constructing the gene modified pig has high feasibility. The obtained TYR gene knock-out pig has the typical characteristics of albinism, can provide a reliable animal model for researching human albinism, can be applied to toxicity and anaphylaxis detection and many other aspects, and is hopeful to become a standardized experimental animal for albinism-like mice.

The invention describes a method of producing extracts from the seeds of meadowfoam, brassicas and crambe plants. A number of subsidiary processes and steps are shown in order to extract differing fractions of oil. Products produced from the above method are also described including uses and methods of these products which include a variety of skin conditions including eczema, facial eczema, dermatitis, external ulcers, welts, rashes, insect bites, allergic reactions and other irritations, burns, wounds, psoriasis, acneiform eruptions, dryness, dry skin, irritation, skin atrophy, secondary infections and the like. The extracts are also described as being a useful compound for treatment of the symptoms of such skin conditions as described above. In particular the use and extraction of glucosinolate (GSL), thiocyanates (TCL) and isothiocyanates (ITCL) is described.

The present invention provides methods of treating IgE-associated disorders and compositions for use therein. The methods are particularly useful in treatment of allergies and allergy-related disorders. The methods generally comprise administering an IgE inhibitor (such as anti-IgE antibody) and an antigen and / or immunostimulatory polynucleotide sequence (ISS). These combination methods offer significant advantages, such as allowing more aggressive therapy while reducing unwanted side effects, such as anaphylaxis.

The invention discloses a high-yield glucosamine gene engineering bacterium and an application thereof; the gene engineering bacterium E. coli-glmS-gnal-delta nagE is obtained by introducing a glucosamine synthase gene (glmS) and a glucosamine acetylase gene (gnal) into escherichia coli E. coli K-12, and knocking out an encoding gene nagE of an acetyl-glucosamine phosphate transport system; the bacterial strain is applicable to the fermentation production of glucosamine, has the advantages of high production intensity, low production cost, less environmental pollution, no allergic reaction, and the like; and the obtained glucosamine is widely applicable to fields such as medicin, food, etc.

The invention discloses a recombinant human collagen and an application thereof. An amino acid sequence of the protein is shown as SEQ ID NO. 3, the nucleotide sequence of the protein-coding gene is shown as SEQ ID NO. 1. The recombinant human collagen of the invention has very good hydrophilicity and stability, and the amino acid composition thereof is 100% identical to the corresponding amino acid sequence of the natural collagen, and the amount of expressed protein can account for about 25% of the total protein of the thalline, per milliliter of the bacteria liquid precipitate contains 0.25mg of the target protein, and the production cost is very low and the cycle is short. The prepared collagen is applied to the human body without immunological rejection and allergic reaction, and canbe widely applied to the biomedicine and cosmetics industries.

Pharmacological compositions, and methods for administration, of the type employing an iron oxide complex with a polyol or polyether. The methods of administration may comprise parenteral administration of an effective dose of the complex formulated in a biocompatible liquid delivered at a rate of from about 1 mL / sec to less than 1 mL / min and wherein upon administration the complex provides minimal detectable free iron in a subject, and minimal incidence of anaphylaxis. The pharmacological compositions are of the type employing a polyol or polyether iron oxide complex, which, upon parenteral administration to a subject, are substantially immunosilent, provide minimal anaphylaxis and minimal free iron, and undergo minimal dissolution in vivo.

The invention provides formula powder for phenylketonuria children and a preparation method thereof. The formula powder comprises solid glucose syrup, amino acid, fatty acid, nucleotide, fish oil, dietary fiber, composite vitamins, composite mineral substances and an emulsifier, and is prepared by using a wet-method preparation process of materials. According to the formula powder, special free amino acid is adopted, a proper amount of free L-tyrosine is screened and optimized, and phenylalanine is removed, so that the physiological needs of sick children are met, and at the same time hypersensitivity of phenylketonuria infants is effectively prevented; in the formula, the components have the mutual synergistic effect, the powder is approximate to breast milk in absorption, taste and the like, children can absorb sufficient nutrition after taking the powder, and meanwhile anaphylaxis such as diarrhea can be effectively reduced; and the formula powder is simple in preparation method and applicable to requirements of large-scale industrial production.

As a pet food produced to contain no proteins that can become allergens, a pet food that contains 1 or more types of amino acids or salts thereof instead of protein raw materials that can become allergens or a pet food produced to contain, in addition to the above amino acid(s), 1 or more types of protein raw materials with low allergenicity selected from any of potato, sweet potato, rice, foxtail millet, barnyard millet, kaoliang, corn, pea, brewer's yeast, and baker's yeast is provided.

Methods of treating autoimmune diseases, allergic responses, cancer, inflammatory diseases, or fibrosis in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.

The present invention relates to IgE-dependent histamine releasing factor (HRF) and HRF-binding peptides, more precisely, deletion forms of HRF which are able to be formed as dimers containing amino acid sequence represented by SEQ ID NO:3, genes encoding thereof and novel HRF-binding peptides having an activity of inhibiting HRF. The deletion forms of HRF which are able to be formed as dimers of the present invention induces intracellular secretion of histamine and IL-8, making an excellent candidate for a drug for inhibiting allergic reaction triggered by HRF and a kit for detecting HRF in serum of an allergy patient. In addition, novel HFR-binding peptides of the present invention bind to HRF to inhibit the actions of HFR, so they can be effectively used for the prevention and the treatment of allergic diseases of animals including asthma and rhinitis or malaria.

Materials for soft tissue augmentation in mammals are prepared by cross-linking blood plasma proteins, preferably with a zero-length cross-linking agent. The cross-linked blood plasma proteins can be dialyzed and autoclaved. Such materials are non-antigenic, exhibit decreased allergic response, and have increased longevity with respect to proteolytic attack from natural proteases. The appearance and / or feel of soft tissue defects and / or imperfections in skin can be improved by injecting such materials into an intradermal compartment of a patient's skin.

The invention relates to high-effective mosquito repelling liquid medicine which is characterized by comprising the following components by weight percent: 2%-7% of N, N-Diethyl-m-toluamide, 0.2%-2% of glycyrrhiza extract (0.1%-90% of glycyrrhizinic acid or glycyrrhetinic acid or physiologically acceptable salt thereof), 0.2%-2% of flavescens extract (0%-90% of matrine or oxymatrine or physiologically acceptable salt thereof), 0%-50% of menthol or borneol and 0.01%-2% of plant essential oil. The high-effective mosquito repelling liquid medicine is the hormone-free preparation made of pure Chinese herbal medicine for external application and is prepared by uniquely combining the high-effective repellent with the components having the anti-inflammatory, the antibacterial and the antipruritic effect, thereby being innovative. The high-effective mosquito repelling liquid medicine of the invention has the function of repelling the mosquito, relieving the itching, refreshing the consciousness and protecting the skin from the insect bite and can repel the mosquito for 5-7 hours. The high-effective mosquito repelling liquid medicine of the invention is non-toxic to the skin and mucous membrane, can not cause the allergic reaction and has higher stability.

The invention discloses an effective skin care product having effects of whitening skin and removing freckles and a preparation method of the skin care product. The skin care product is prepared from raw materials in percentage by weight as follows: 5%-8% of Asian Betula alba juice, 2.5%-4.5% of the other effective skin care product additive, 10%-12% of glycerin, 1.5%-2.0% of ceramide 3, 0.8%-1.5% of sodium hyaluronate, 1.5%-2.5% of polysorbate -20 and 73%-78.7% of water, wherein the other effective skin care product additive is prepared from raw materials in percentage by weight as follows: 5%-8% of a glycyrrhiza glabra root extract, 3%-5% of a strawberry extract, 3%-7% of arbutin and 4.5%-7.5% of aloe vera leaf juice. Trials on the effective skin care product having effects of whitening skin and removing freckles by consumers find that the skin care product has effects of whitening skin, removing freckles and resisting oxidation; during the trials, feedback of trial allergic reactions is not received, and the skin care product is suitable for people with various skin types at ages prone to freckles (20-50 years old).

This invention provides an altered kosher kappa casein polypeptide having at least one altered amino acid in a defined amino acid stretch. The defined amino acid stretch contributes to an allergic reaction induced by a kosher wild-type casein polypeptide in a human subject. Moreover, the defined amino acid stretch is expressed solely in kosher animals. The invention further provides an expression system for expressing the altered kosher casein polypeptide.